These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8684381

  • 1. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L, De Salvia M, Jenner P, Marsden CD.
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [Abstract] [Full Text] [Related]

  • 2. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 3. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 4. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 6. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset.
    Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RK, Jenner P.
    Clin Neuropharmacol; 2000 Apr; 23(3):133-42. PubMed ID: 10895396
    [Abstract] [Full Text] [Related]

  • 7. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M, Stahl S, Jenner P, Marsden CD.
    Mov Disord; 1987 Apr; 2(1):37-45. PubMed ID: 2904119
    [Abstract] [Full Text] [Related]

  • 8. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 9. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 10. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P.
    Clin Neuropharmacol; 2006 Sep 28; 29(3):112-25. PubMed ID: 16772809
    [Abstract] [Full Text] [Related]

  • 11. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Sep 28; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 12. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Ann Neurol; 1998 Apr 28; 43(4):507-13. PubMed ID: 9546333
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 28; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 18. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.
    Mov Disord; 2006 Dec 28; 21(12):2090-5. PubMed ID: 16991143
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.